Mary Kay Inc. Recommits to Responsible and Sustainable Water Management Following World Water Day 2022
24.3.2022 15:02:00 EET | Business Wire | Press release
Water is essential to life in all its forms and to the ongoing development of a healthy and sustainable future. According to the World Economic Forum, environmental risks and the impact on natural ecosystems and resources continues to be a top global risk.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220324005126/en/
Richard R. Rogers (R3) Manufacturing/R&D Center in Lewisville, Texas, U.S.A (Photo: Mary Kay Inc.)
This World Water Day, Mary Kay Inc. recommits to responsible and sustainable water management to ensure the ongoing availability of water as an essential resource to meet the needs of the environment and communities around the world.
Water is at the heart of Mary Kay’s sustainability strategy and crucial to its manufacturing processes. Implementing good water stewardship principles is critical for Mary Kay to reach our sustainability goals. We strive to ensure water use for human and economic needs does not disrupt sustainable water cycles or cause ongoing harm to nature and biodiversity. Recent water efforts at Mary Kay facilities include:
- Water use at U.S. Mary Kay-owned facilities decreased 36% from 2012-2017.
-
At Mary Kay’s manufacturing facility in Hangzhou, China, significant strides toward water conservation include:
- Reduced potable water use by 34%, which saves approximately 913,480 gallons of potable water per year.
- Reverse Osmosis (RO) reject water reuse: The purifying water equipment produces a large amount of concentrated water discharge in the operation process. By collecting concentrated water and passing it through the circulation system, concentrated water will be reused through the fire tower and air-cooling tower system as a supplementary water source.
- Wastewater treatment upgrade: To mitigate the environmental impact of wastewater in its manufacturing processes, Mary Kay China invested in an advanced membrane bioreactor (MBR) process using existing infrastructure to improve the capacity of wastewater treatment and reduce sludge discharge by 40%.
“As a global sustainability advocate, Mary Kay is dedicated to playing an important role in collective efforts to cause no harm to the environment and to ensure communities and economies prosper,” said Deborah Gibbins, Chief Operating Officer at Mary Kay Inc. “Mary Kay will continue to build upon its progress and work toward its commitment of reducing water utilization in our manufacturing processes by 30% by the year 2030 versus a 2020 baseline per kilogram bulk produced. Achieving Alliance for Water Stewardship (AWS) Core Certification for Mary Kay manufacturing facilities in the U.S. and China will help move us closer to our goals.”
Several key components of Mary Kay’s decade of action include:
- A current signatory of the UN Ocean Principles and CEO Water Mandate.
-
Continuing its 32-year partnership with The Nature Conservancy and supporting 11 global water projects in 2022 focusing on:
- Global ocean protection to improve ocean health for nature and people;
- Restoring Asia Pacific Shellfish Reefs in Australia, Hong Kong, China, the Coral Triangle, and the Cakaulevu Reef (also called the Great Sea Reef);
- Supporting Women Leaders in The Pacific in Papua New Guinea (Mangroves, Women, and Markets) and the Solomon Islands (Community Health and Resilience);
- Coastal Conservation and Restoration in the Gulf Coast (Protecting the Gulf Coast Coastal Wetlands);
- Improving Fisheries in Mexico (Improving Fisheries and Empowering Communities); and
- Collaborating with partners in Europe supporting native oyster restoration projects in England, Scotland, Ireland, France, the Netherlands, Germany, and Sweden.
- Joining Alliance for Water Stewardship and working to achieve certification of our two manufacturing facilities by 2025.
To read more about Mary Kay’s commitment to sustainability, visit marykayglobal.com/sustainability and download Mary Kay’s global sustainability strategy, Enriching Lives Today for a Sustainable Tomorrow.
About Mary Kay Inc.
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn or follow us on Twitter.
About The Nature Conservancy
The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our world's toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters and oceans at an unprecedented scale, providing food and water sustainably and helping make cities more sustainable. Working in 79 countries and territories, we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit www.nature.org or follow @nature_press on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005126/en/
Contact information
Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
